Ponatinib · ICLUSIG

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Iclusig 15 mg (Otsuka): CML resistant or intolerant to prior therapy; relapsed or refractory Ph+ ALL
Product first approved 2016sec.gov
EU
  • Iclusig is indicated as monotherapy in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Iclusig...
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Acute Lymphoblastic Leukemia
NCT04530565 · National Cancer Institute (NCI)
2021-01-25 – 2028-07-01 · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
What this study did
Chronic Myeloid Leukemia
NCT02627677 · Ariad Pharmaceuticals
2015-12-31 – 2021-01-20 · Chronic Phase Chronic Myeloid Leukemia
What this study did
Phase 2/3 (2)
Acute Lymphoblastic Leukemia
NCT06860269 · Assistance Publique - Hôpitaux de Paris
2025-05-06 – 2035-03-15 · Acute Lymphoblastic Leukemia
What this study did
Other / comorbidity
NCT01761747 · Dana-Farber Cancer Institute
2013-01 – 2014-06 · Non-Small Cell Lung Cancer, Head and Neck Cancer
What this study did
Phase 2 (41)
Acute Lymphoblastic Leukemia
NCT06061094 · Goethe University
2023-07-14 – 2029-07-01 · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
What this study did
NCT04845035 · University of Michigan Rogel Cancer Center
2024-01 – 2029-01 · Acute Lymphoblastic Leukemia
What this study did
NCT07224100 · University of Washington
2026-03-30 – 2028-07-31 · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
What this study did
NCT05306301 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2022-10-05 – 2028-07-01 · Chemotherapy, Leukemia, Acute Lymphoblastic
What this study did
NCT04747912 · University of Chicago
2021-03-02 – 2028-03-01 · Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
What this study did
NCT03263572 · M.D. Anderson Cancer Center
2017-11-29 – 2027-11-30 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)
What this study did
NCT01424982 · M.D. Anderson Cancer Center
2011-10-05 – 2027-10-31 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
What this study did
NCT03147612 · M.D. Anderson Cancer Center
2018-02-08 – 2027-02-28 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
What this study did
NCT03739814 · National Cancer Institute (NCI)
2019-05-08 – 2027-02-01 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
What this study did
NCT04233346 · Otsuka Beijing Research Institute
2020-07-09 – 2026-09-08 · Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
What this study did
NCT05268003 · M.D. Anderson Cancer Center
2022-06-07 – 2026-04-21 · Acute Lymphoblastic Leukemia, Leukemia
What this study did
NCT04475731 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2021-05-04 – 2024-11 · Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
What this study did
NCT04554459 · Institute of Hematology and Blood Transfusion, Czech Republic
2021-02-16 – 2024-07-01 · Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed
What this study did
NCT02776605 · PETHEMA Foundation
2016-06 – 2023-08 · ALL
What this study did
NCT01641107 · Incyte Corporation
2014-12-04 – 2021-09-30 · Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia
What this study did
NCT01620216 · OHSU Knight Cancer Institute
2012-05-11 – 2017-04-30 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
What this study did
Chronic Myeloid Leukemia
NCT01746836 · M.D. Anderson Cancer Center
2013-01-17 – 2030-12-31 · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
What this study did
NCT04070443 · Centre Leon Berard
2019-11-13 – 2029-06-01 · Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia
What this study did
NCT06514534 · Novartis Pharmaceuticals
2025-02-18 – 2029-02-18 · Chronic Myeloid Leukemia (CML)
What this study did
NCT04188405 · M.D. Anderson Cancer Center
2020-05-17 – 2026-06-02 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
What this study did
NCT04160546 · Fundacion CRIS de Investigación para Vencer el Cáncer
2020-01-17 – 2025-12-31 · Chronic Myeloid Leukemia, Chronic Phase
What this study did
NCT04709731 · Associazione Italiana Pazienti Leucemia Mieloide Cronica
2021-02-01 – 2025-04-01 · Chronic Myeloid Leukemia (CML)
What this study did
NCT04043676 · Fundación Teófilo Hernando, Spain
2019-04-30 – 2023-04-30 · Chronic Myeloid Leukemia
What this study did
NCT02398825 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2016-06-23 – 2022-12-27 · Chronic Myeloid Leukemia, Chronic Phase, Adults
What this study did
NCT01570868 · M.D. Anderson Cancer Center
2012-04 – 2016-05 · Leukemia
What this study did
Other / comorbidity
NCT06813079 · University Health Network, Toronto
2025-04-07 – 2028-02-17 · Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor
What this study did
NCT03895671 · Versailles Hospital
2019-06-19 – 2025-12-31 · CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT03690115 · Versailles Hospital
2019-12-02 – 2024-12-31 · Leukemia, Myeloid, Acute
What this study did
NCT03807479 · GWT-TUD GmbH
2018-12-11 – 2023-08-31 · Leukemia, Myeloid, Chronic-Phase
What this study did
NCT02272998 · Sameek Roychowdhury
2015-02-24 – 2022-11-17 · Malignant Neoplasm
What this study did
NCT03838692 · Antonio Fojo
2019-07-26 – 2021-06-14 · Medullary Thyroid Cancer
What this study did
NCT03171389 · Sebastian Bauer
2017-03-22 – 2020-09-22 · GIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation
What this study did
NCT02265341 · Mayo Clinic
2014-12 – 2019-06-14 · Malignant Hepatobiliary Neoplasm
What this study did
NCT01813734 · Massachusetts General Hospital
2013-09 – 2018-08 · Non Small Cell Lung Cancer
What this study did
NCT02478164 · Dana-Farber Cancer Institute
2015-07-13 – 2018-05-09 · Glioblastoma
What this study did
NCT01935336 · University of Colorado, Denver
2013-09-24 – 2017-11 · Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT01874665 · Ariad Pharmaceuticals
2013-06-05 – 2016-07-31 · GIST
What this study did
NCT01838642 · National Institutes of Health Clinical Center (CC)
2013-03 – 2016-01 · Thyroid Neoplasms
What this study did
Phase 1/2 (8)
Acute Lymphoblastic Leukemia
NCT03934372 · Incyte Biosciences International Sàrl
2020-01-29 – 2028-02-01 · Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Leukemia, Lymphoma, Solid Tumors
What this study did
NCT06207123 · University of Chicago
2024-09-13 – 2026-12-01 · Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
What this study did
NCT04501614 · Takeda
2021-02-24 – 2024-07-19 · Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
What this study did
NCT03576547 · M.D. Anderson Cancer Center
2018-06-26 – 2024-06-19 · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, t(9;22)
What this study did
NCT01667133 · Ariad Pharmaceuticals
2012-08-31 – 2018-08-02 · Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
What this study did
Other / comorbidity
NCT02428543 · Versailles Hospital
2013-07 – 2023-10-03 · Acute Myeloid Lukemia
What this study did
NCT03704688 · Memorial Sloan Kettering Cancer Center
2018-10-09 – 2022-02-04 · Non Small Cell Lung Cancer, KRAS Gene Mutation
What this study did
NCT02829840 · M.D. Anderson Cancer Center
2016-09 – 2021-09 · Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome
What this study did
Phase 1 (3)
Acute Lymphoblastic Leukemia
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02779283 · OHSU Knight Cancer Institute
2016-01-13 – 2018-09-20 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
What this study did
Chronic Myeloid Leukemia
NCT00660920 · Ariad Pharmaceuticals
2008-06 – 2016-05 · Chronic Myelogenous Leukemia, Hematologic Malignancies
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT01888562 · Washington University School of Medicine
2016-01 – 2023-07 · Endometrial Neoplasms
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Acute Lymphoblastic Leukemia
NCT04688983 · Cardiff University
2021-01 – 2026-01 · Acute Lymphoblastic Leukemia, Adult
What this study did

Competitive landscape

This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ponatinib (ICLUSIG): this drugApprovedSmall moleculeBCR-ABL (including T315I)Partial signalFeatured results are non-efficacy only in this race
BlinatumomabApprovedMultispecific antibodyCD19 x CD3Weak signal
NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)ApprovedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
ZiftomenibPhase 1/2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ICLUSIG (Ponatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06207123 · CT.gov ↗
What to watch
2027 (5)
February 2027 (2)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-02-01 · NCT03739814 · CT.gov ↗
What to watch
Phase 2Chronic Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02-28 · NCT03147612 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-09 · NCT04722848 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Chronic Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-10-31 · NCT01424982 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Chronic Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-30 · NCT03263572 · CT.gov ↗
What to watch
2028 (5)
February 2028 (2)
Phase 1/2Chronic Myeloid LeukemiaRecruiting
Est. primary completion 2028-02-01 · NCT03934372 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT04747912 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2028-07-01 · NCT04530565 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-07-31 · NCT07224100 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 2Chronic Myeloid LeukemiaRecruiting
Est. primary completion 2029-02-17 · NCT06514534 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Chronic Myeloid LeukemiaActive not recruiting
Est. primary completion 2029-06-01 · NCT04070443 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-07-01 · NCT06061094 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Chronic Myeloid LeukemiaRecruiting
Est. primary completion 2030-12-31 · NCT01746836 · CT.gov ↗
What to watch
2035 (1)
March 2035 (1)
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2035-03-15 · NCT06860269 · CT.gov ↗
What to watch

See the full readout calendar ↗